Literature DB >> 6619962

Biodistribution and dosimetry of N-isopropyl-p-[123I]iodoamphetamine in the primate.

B L Holman, R E Zimmerman, J R Schapiro, M L Kaplan, A G Jones, T C Hill.   

Abstract

The biodistribution of N-isopropyl-p-[123I]iodoamphetamine (I-123 IMP) in the Macaca fascicularis monkey was determined at 15 min and at 1, 4, 24, and 48 hr after intravenous injection. Brain uptake was 7.8% of the injected dose at 1 hr, with little change in concentration between 15 min and 1 hr, falling thereafter. Eye uptake reached a maximum of 0.23% of injected dose at 24 hr, with activity primarily in the pigmented layers. The human absorbed radiation dose was calculated on the basis of biodistribution data. The critical organ is the eye (0.407 rad/mCi of I-123 IMP). The eye dose increased to 1.11 rad/mCi with 4% contamination from I-124 IMP and to 0.535 rad/mCi with 0.4% contamination from I-125 IMP. The absorbed dose to the liver was 0.127 rad/mCi for pure I-123 IMP and the thyroid dose was 0.120 rad/mCi, both increasing with either I-124 or I-125 contamination. While delayed eye uptake has not yet been reported in the human, care should be exercised in limiting the amount of contaminating I-124 or I-125 to the lowest practical level.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6619962

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

1.  Prolonged lung retention of 123I-IMP in pulmonary fibrosis.

Authors:  H Ikeda; M Itasaka; K Takahashi; A Komatani
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

2.  Change of accumulation and filling pattern in evolution of cerebral infarction with I-123 IMP brain SPECT.

Authors:  K Hayashida; T Nishimura; S Imakita; T Uehara; M Nakamura; T Tsuchiya; Y Hasegawa
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

3.  Noninvasive diagnostics supporting system for choroidal melanoma: a pilot study.

Authors:  Ori Kameyama; Yoshihiko Usui; Keisuke Kimura; Atsushi Nakamura; Takayuki Sota; Hiroshi Goto
Journal:  Jpn J Ophthalmol       Date:  2014-10-08       Impact factor: 2.447

4.  Brain affinity of the ruthenocene analogue of N-isopropyl-amphetamine labeled with gamma-emitters.

Authors:  M Wenzel; D Preiss
Journal:  Naturwissenschaften       Date:  1986-08

5.  The influence of age on N-isopropyl-p-[123I]iodoamphetamine accumulation in the human heart.

Authors:  M Nakajo; Y Nakabeppu; S Iwashita; S Shinohara
Journal:  Ann Nucl Med       Date:  1990-07       Impact factor: 2.668

6.  Early and delayed single photon emission CT in various cerebral diseases using N-isopropyl-p-(123I)iodoamphetamine.

Authors:  T Ueda; K Kinoshita; K Watanabe; H Hoshi; S Jinnouchi
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

7.  Localization of IBF as a D-2 dopamine receptor imaging agent in nonhuman primates.

Authors:  J J Billings; Y Z Guo; M P Kung; H F Kung
Journal:  Eur J Nucl Med       Date:  1993-12

8.  Localization of melanoma with radiolabelled monoclonal antibody fragments and iodoamphetamine.

Authors:  K Liewendahl; A L Kairento; S Pyrhönen; K Franssila; S Asko-Seljavaara; L Lindroth; P Virkkunen; J Launes
Journal:  Eur J Nucl Med       Date:  1986

9.  N-isopropyl-p[123I]iodoamphetamine, a new agent for lung imaging studies.

Authors:  N Van Zandwijk; A Zwijnenburg; C A Hoefnagel; H R Marcuse
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

10.  Evaluation of portal circulation through the superior mesenteric vein with an enteric capsule of [123I]iodoamphetamine.

Authors:  S Shiomi; T Kuroki; Y Miyazawa; T Ueda; T Takeda; S Nishiguchi; S Nakajima; K Kobayashi; H Ochi
Journal:  J Gastroenterol       Date:  1995-02       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.